A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, January-March 2023
• By Deanna Kamienski and Maureen Riordan
During Q1, biopharma merger and acquisition deal value reached $51.9bn and drew in $38.1bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $2.7bn.
• Source: Alamy
Biopharma merger and acquisition value for the opening quarter of 2023 reached $51.9bn from 32 transactions, 13 of which had disclosed values. Making up 83% of that total is Pfizer’s proposed $43bn buy of Seagen This deal and four other transactions were the only M&As to hit or exceed the billion-dollar mark during Q1 (see Exhibit 1).
The proposed Pfizer/Seagen deal – which marks the largest M&A of the quarter – is expected to close in late...
